Rabies virus vaccine as an immune adjuvant against cancers and glioblastoma: new studies may resurrect a neglected potential

• M. A. Altinoz ^[2] ; S. Guloksuz ^[1] ; İ. Elmaci ^[3]
  1. [1] Maastricht University Medical Centre

     Maastricht University Medical Centre

     Países Bajos

     
  2. [2] Neuro-Academy Research GroupIstanbulTurkey
  3. [3] Memorial HospitalIstanbulTurkey

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 7, 2017, págs. 785-792
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • To review the literature about the use of Rabies Virus-Vaccine (RV-V) as an anticancer immunotherapeutic modality in the light of recent findings. The literature search in relevant databases with the following key words: Rabies virus, cancer, remission. Remissions occured following RV-V injections in patients with cervical cancer and melanoma. Pilot clinical studies showed that RV-V injections enhanced survival in glioblastoma patients, which is supported by findings in GL261 mouse glioma model. If public health studies demonstrate protective role of RV-V against certain types of cancers, it can be benefitted as a novel immune adjuvant in clinic.